FEPRAZONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H20N2O2
Molecular Weight	320.385
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)=CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=RBBWCVQDXDFISW-UHFFFAOYSA-N

InChI=1S/C20H20N2O2/c1-15(2)13-14-18-19(23)21(16-9-5-3-6-10-16)22(20(18)24)17-11-7-4-8-12-17/h3-13,18H,14H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C20H20N2O2
Molecular Weight	320.385
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1094965
Curator's Comment: description was created based on several sources, including, https://www.jstage.jst.go.jp/article/cpb1958/34/1/34_1_214/_pdf

Feprazone is an anti-inflammatory compound developed for the treatment of such conditions as osteoarthritis, rheumatoid arthritis, rheumatic fever and gouty arthritis. The drug was tested in phase III of clinical trials, however its further faith is unknown.

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 320 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1094965	Palliative	Phase III 665	Unknown Approved Use Unknown
Osteoarthritis 157 Sources: http://en.cnki.com.cn/Article_en/CJFDTOTAL-XYYL806.006.htm	Palliative	Phase III 665	Unknown Approved Use Unknown
Rheumatic fever 6 Sources: http://en.cnki.com.cn/Article_en/CJFDTOTAL-XYYL806.006.htm	Palliative	Phase III 665	Unknown Approved Use Unknown
Gouty arthritis 4 Sources: http://en.cnki.com.cn/Article_en/CJFDTOTAL-XYYL806.006.htm	Palliative	Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
9.5 μg/mL CLINICAL TRIAL https://doi.org/10.3109/00498258809041724	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		FEPRAZONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

AUC

Value	Dose	Analyte	Population
854 mg × h/L CLINICAL TRIAL http://dx.doi.org/10.3109/00498259309059434	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
694 mg × h/L CLINICAL TRIAL http://dx.doi.org/10.3109/00498259309059434	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1370 mg × h/L CLINICAL TRIAL http://dx.doi.org/10.3109/00498259309059434	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1640 mg × h/L CLINICAL TRIAL http://dx.doi.org/10.3109/00498259309059434	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1370 mg × h/L CLINICAL TRIAL https://doi.org/10.3109/00498258809041724	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

T_1/2

Value	Dose	Analyte	Population
20.9 h CLINICAL TRIAL http://dx.doi.org/10.3109/00498259309059434	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
24.6 h CLINICAL TRIAL http://dx.doi.org/10.3109/00498259309059434	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
23.3 h CLINICAL TRIAL http://dx.doi.org/10.3109/00498259309059434	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
22.6 h CLINICAL TRIAL http://dx.doi.org/10.3109/00498259309059434	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
23 h CLINICAL TRIAL https://doi.org/10.3109/00498258809041724	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FEPRAZONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

Doses

Dose	Population	Adverse events
5 % 1 times / day multiple, topical Studied dose Dose: 5 %, 1 times / day Route: topical Route: multiple Dose: 5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8458203/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8458203/	Disc. AE: Contact dermatitis... AEs leading to discontinuation/dose reduction: Contact dermatitis (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/8458203/
200 mg 3 times / day multiple, oral Studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/338255	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/338255	Disc. AE: rash... Other AEs: Headaches, Nausea... AEs leading to discontinuation/dose reduction: rash (severe, 1 pt) Other AEs: Headaches (6 patients) Nausea (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/338255

AEs

AE	Significance	Dose	Population
Contact dermatitis	3 patients Disc. AE	5 % 1 times / day multiple, topical Studied dose Dose: 5 %, 1 times / day Route: topical Route: multiple Dose: 5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8458203/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8458203/
Nausea	4 patients	200 mg 3 times / day multiple, oral Studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/338255	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/338255
Headaches	6 patients	200 mg 3 times / day multiple, oral Studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/338255	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/338255
rash	severe, 1 pt Disc. AE	200 mg 3 times / day multiple, oral Studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/338255	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/338255

PubMed

Title	Date	PubMed
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001-11	11792017

Patents

Sample Use Guides

In Vivo Use Guide

150 mg four times daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:32:38 GMT 2025` Edited by `admin` on `Mon Mar 31 18:32:38 GMT 2025`
Record UNII	7BVX6J0CGR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FEPRAZONE

Official Name

English

DA-2370

Preferred Name

English

4-(3-METHYL-2-BUTENYL)-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE

Systematic Name

English

FEPRAZONE [JAN]

Common Name

English

FEPRAZONE [MART.]

Common Name

English

DA 2370

Code

English

feprazone [INN]

Common Name

English

Feprazone [WHO-DD]

Common Name

English

FEPRAZONE [MI]

Common Name

English

Classification Tree Code System Code

WHO-ATC

M01AX18